Mail None declared Paolo Bellavite features a consultancy agreement with Vanda s.r.l. (Frascati, Rome). The other authors have no competing interests to declareIn the previous two years, the coronavirus disease 2019 (COVID-19) pandemic has driven investigational studies and controlled clinical trials on antiviral treatments and vaccines which have undergone regulatory approval. Now that the severe acute respiratory syndrome coronavirus two (SARS-CoV-2) and its variants might develop into endemic more than time, there remains a need to determine drugs that treat the symptoms of COVID-19 and prevent progression toward severe situations, hospitalization, and death. Understanding the molecular mechanisms of SARS-CoV-2 infection is extremely critical for the development of productive therapies against COVID-19. This overview outlines the key pathways involved inside the host response to SARS-CoV-2 infection and discusses the potential part of antioxidant and anti-inflammatory pharmacological approaches for the management of early mild-to-moderate COVID-19, employing the examples of combined indomethacin, low-dose aspirin, omeprazole, hesperidin, quercetin, and vitamin C. The pharmacological targets of these substances are described here for their probable synergism in counteracting SARS-CoV-2 replication and progression of the infection in the upper respiratory airways for the blood, avoiding vascular complications and cytokine and bradykinin storms.MCP-4/CCL13 Protein supplier Key phrases: Anti-InflammatoryAgents,Non-Steroidal OVID-19 lavonoids esperidin ndomethacinQuercetin medscimonit/abstract/index/idArt/Full-text PDF:–This operate is licensed beneath Inventive Frequent AttributionNonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)e936292-Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]REVIEW ARTICLESFazio S. et al: Multitherapy of early COVID-19 Med Sci Monit, 2022; 28: eBackgroundThe serious acute respiratory syndrome, caused by SARS-CoV-2, leads to a wide spectrum of multi-organ pathologies, called coronavirus illness 2019 (COVID-19). Though there is of course a terrific deal of pharmacological analysis going on, no specific definitive drugs are presently out there for treating low-tomoderate-risk COVID-19. Patients admitted to hospitals within the most advanced countries receive intensive care, however the trouble of lack of particular care mostly concerns the care provided inside the early stages in the illness and hence house care. The Italian Ministry of Well being as well as the Italian Medicines Agency (AIFA) have issued recommendations for the household management of patients with COVID-19, which adhere to the most up-to-date acquisitions of evidence-based medicine (aifa.MFAP4 Protein Synonyms gov.PMID:24463635 it/aggiornamento-sui-farmaci-utilizzabili-per-il-trattamentodella-malattia-covid19). Low-risk sufferers are defined there by the absence of enhanced threat factors (eg, neoplastic pathologies or immunosuppression) and around the basis of the following characteristics: a) flu-like symptoms (eg, rhinitis, cough without breathing issues, myalgia, headache); b) absence of dyspnea and tachypnea (documenting, whenever doable, the presence of an SpO2 92 ); c) fever eight or 38 , for significantly less than 72 h; d) gastro-enteric symptoms (in the absence of dehydration and/or numerous diarrheal discharges); e) asthenia, ageusia/dysgeusia/anosmia. In such sufferers, lacking a extensively approved therapeutic tactic and pending evidencebased guidance,.
